Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 6 |
List of Tables | 6 | 1 |
List of Figures | 7 | 1 |
Introduction | 8 | 1 |
Global Markets Direct Report Coverage | 8 | 1 |
Diphtheria Overview | 9 | 1 |
Therapeutics Development | 10 | 2 |
Pipeline Products for Diphtheria Overview | 10 | 1 |
Pipeline Products for Diphtheria Comparative Analysis | 11 | 1 |
Diphtheria Therapeutics under Development by Companies | 12 | 2 |
Diphtheria Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
Diphtheria Pipeline Products Glance | 15 | 3 |
Late Stage Products | 15 | 1 |
Clinical Stage Products | 16 | 1 |
Early Stage Products | 17 | 1 |
Diphtheria Products under Development by Companies | 18 | 2 |
Diphtheria Products under Investigation by Universities/Institutes | 20 | 1 |
Diphtheria Companies Involved in Therapeutics Development | 21 | 16 |
Beijing Minhai Biotechnology Co., Ltd | 21 | 1 |
BioClonetics Immunotherapeutics, Inc. | 22 | 1 |
Biological E. Limited | 23 | 1 |
Boryung Pharmaceutical Co., Ltd. | 24 | 1 |
Daiichi Sankyo Company, Limited | 25 | 1 |
GlaxoSmithKline Plc | 26 | 1 |
Green Cross Corporation | 27 | 1 |
Indian Immunologicals Limited | 28 | 1 |
Kaketsuken K.K. | 29 | 1 |
LG Life Science LTD. | 30 | 1 |
Panacea Biotec Limited | 31 | 1 |
Prometheon Pharma, LLC | 32 | 1 |
Sanofi Pasteur SA | 33 | 1 |
Serum Institute of India Pvt Ltd | 34 | 1 |
Sinovac Biotech Ltd. | 35 | 1 |
Zydus Cadila Healthcare Limited | 36 | 1 |
Diphtheria Therapeutics Assessment | 37 | 8 |
Assessment by Monotherapy Products | 37 | 1 |
Assessment by Combination Products | 38 | 1 |
Assessment by Target | 39 | 2 |
Assessment by Route of Administration | 41 | 2 |
Assessment by Molecule Type | 43 | 2 |
Drug Profiles | 45 | 33 |
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine Drug Profile | 45 | 1 |
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine Drug Profile | 46 | 1 |
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine Drug Profile | 47 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile | 48 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine Drug Profile | 49 | 1 |
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine Drug Profile | 50 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile | 51 | 1 |
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile | 52 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine Drug Profile | 53 | 1 |
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine Drug Profile | 54 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 55 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 56 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 57 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 58 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile | 59 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 Drug Profile | 60 | 1 |
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 Drug Profile | 61 | 1 |
(diphtheria + pertussis (whole cell) + tetanus) vaccine Drug Profile | 62 | 1 |
(diphtheria + pertussis (whole-cell) + tetanus) vaccine Drug Profile | 63 | 1 |
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine Drug Profile | 64 | 2 |
(diphtheria + tetanus) vaccine Drug Profile | 66 | 1 |
BVN-002 Drug Profile | 67 | 1 |
diphtheria + pertussis(acellular) + tetanus vaccine Drug Profile | 68 | 1 |
diphtheria vaccine Drug Profile | 69 | 1 |
Eupenta Drug Profile | 70 | 1 |
GC-1107 Drug Profile | 71 | 1 |
GC-3111A Drug Profile | 72 | 1 |
KD-370 Drug Profile | 73 | 1 |
LBVD Drug Profile | 74 | 1 |
Monoclonal Antibody for Diphtheria Drug Profile | 75 | 1 |
VN-0103 Drug Profile | 76 | 1 |
VN-0105 Drug Profile | 77 | 1 |
Diphtheria Dormant Projects | 78 | 1 |
Diphtheria Discontinued Products | 79 | 1 |
Diphtheria Product Development Milestones | 80 | 1 |
Featured News &Press Releases | 80 | 1 |
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta | 80 | 1 |
Nov 24, 2014: CanSinotech submitted CTA of Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed to CFDA | 80 | 1 |
Appendix | 81 | 2 |
Methodology | 81 | 1 |
Coverage | 81 | 1 |
Secondary Research | 81 | 1 |
Primary Research | 81 | 1 |
Expert Panel Validation | 81 | 1 |
Contact Us | 81 | 1 |
Disclaimer | 82 | 1 |